Hepatocellular carcinoma (HCC) generally develops as a ... The identifiable population at risk makes screening a realistic possibility, and liver imaging is recommended every 6 months for patients ...

In 2005, 1002 (39%) patients, with a mean age of 66.7 ± 8.6 years, responded to this follow-up screening, including 461 (aged 68.3 ± 8.7 years) males and 541 (65.3 ± 8.2 years) females.

Hepatocellular carcinoma, a type of liver cancer, is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths. Screening efforts for this cancer focus on ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...

Disparities in liver cancer risk and outcomes in the LGBTQ community: A literature review. Non-contrast MRI as a surveillance tool for recurrent hepatocellular carcinoma after curative treatment: A ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Other areas of expertise include analyzing treatment outcomes data for patients with gastrointestinal cancers, as well as the identification of new treatments for fibrolamellar hepatocellular ...